Labetalol (versus unexposed) updated on 12-17-2024

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Atrial septal defect2.01 [1.20, 3.37]0%2 studies7,02283not evaluable ROB3.43 [1.68; .]
Congenital heart defects1.34 [0.72, 2.46]60%2 studies43,092123not evaluable ROB-
Hypospadias1.47 [0.35, 6.14]79%2 studies10,28721not evaluable ROB-
Coarctation of aorta4.31 [1.66, 11.17]-1 study23not evaluable ROB8.09 [2.71; .]
Multicystic renal dysplasia3.80 [1.31, 11.05]-1 study1,334not evaluable ROB7.06 [1.94; .]
11 non statistically significant endpoints reported in only one study

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Small for gestational age (weight)1.86 [1.29, 2.68]92%7 studies142,1075,904not evaluable ROB3.13 [1.91; .]
Preterm (< 37 weeks)1.33 [0.50, 3.51]91%3 studies109,7321,627not evaluable ROB-
Low birth weight (< 2500g)5.92 [5.46, 6.41]-1 study20,2133,357not evaluable ROB11.31 [10.40; .]
Very low birth weight (< 1500g)8.60 [7.52, 9.83]-1 study3,6893,357not evaluable ROB16.68 [14.53; .]

Maternal consequences
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Caesarean1.27 [0.43, 3.76]93%3 studies106,1243,535not evaluable ROB-
Preeclampsia1.30 [0.17, 9.84]98%2 studies2,5033,484not evaluable ROB-
Abruptio placentae (retroplacental hematoma)0.27 [0.13, 0.59]-1 study40127not evaluable ROB6.77 [.; 2.79]
Assisted deliveries (forceps, vacuum, ...)0.67 [0.51, 0.89]-1 study8,2833,357not evaluable ROB2.34 [.; 1.50]
1 non statistically significant endpoints reported in only one study

Neonatal disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Neonatal medical care2.05 [1.18, 3.53]0%2 studies84146not evaluable ROB3.51 [1.65; .]
Jaundice / Icterus2.85 [1.60, 5.08]0%2 studies68156not evaluable ROB5.15 [2.58; .]
Low Apgar score (< 7) (at 5 min)2.29 [0.87, 5.98]55%2 studies3,1153,443not evaluable ROB-
Neonatal hypoglycemia1.78 [1.55, 2.04]0%2 studies9466,854not evaluable ROB2.96 [2.48; .]
Fetal distress3.14 [1.01, 9.74]-1 study1732not evaluable ROB5.74 [1.13; .]
Low Apgar score (< 7) (at 1 min)2.71 [2.43, 3.02]-1 study17,1333,357not evaluable ROB4.86 [4.30; .]
Low Apgar score (< 7) (at 10 min)2.43 [1.70, 3.48]-1 study1,4613,357not evaluable ROB4.30 [2.79; .]
Neonatal bradycardia1.34 [1.08, 1.67]-1 study3996,730not evaluable ROB2.01 [1.37; .]
Neonatal disorders (as a whole)4.25 [1.51, 11.98]-1 study2432not evaluable ROB7.97 [2.38; .]
Neonatal hypotension8.02 [2.32, 27.66]-1 study24124not evaluable ROB15.52 [4.08; .]
3 non statistically significant endpoints reported in only one study

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Perinatal death2.08 [1.26, 3.44]-1 study6,0781,452not evaluable ROB3.58 [1.83; .]
1 non statistically significant endpoints reported in only one study

Neuro-developmental disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
2 non statistically significant endpoints reported in only one study

- About - Master protocol - Browse exposition - RSS - Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons